Last checked at 5 Jun 2017 07:00
5 June 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at ShareSoc Growth Company Seminar
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the ShareSoc Growth Company Seminar on Wednesday 14th June in London at Capita Asset Services, 40 Dukes Place, London EC3A 7NH.
The evening event, which begins with registration at 17:00, provides an opportunity for investors to hear about the Company's Affimer® technology, its development plans and to discuss these with Alastair and with Dr Amrik Basran, Avacta's Chief Scientific Officer.
ENDS
NOTES
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking
WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang | Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Zyme Communications (Trade and Regional Media) Katie Odgaard
FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins | Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com |
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.